Imugene Limited

ASX:IMU Stock Report

Market Cap: AU$90.2m

Imugene Valuation

Is IMU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMU's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMU?

Key metric: As IMU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IMU. This is calculated by dividing IMU's market cap by their current revenue.
What is IMU's PS Ratio?
PS Ratio20.5x
SalesAU$4.40m
Market CapAU$90.23m

Price to Sales Ratio vs Peers

How does IMU's PS Ratio compare to its peers?

The above table shows the PS ratio for IMU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average27.6x
CYP Cynata Therapeutics
32.7x54.22%AU$61.7m
DXB Dimerix
50.5xn/aAU$285.2m
ATH Alterity Therapeutics
18x54.51%AU$97.9m
NOX Noxopharm
9.2xn/aAU$26.0m
IMU Imugene
20.5x92.98%AU$90.2m

Price-To-Sales vs Peers: IMU is good value based on its Price-To-Sales Ratio (20.5x) compared to the peer average (27.6x).

Price to Sales Ratio vs Industry

How does IMU's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
CSL CSL
3.6x4.36%US$55.78b
ARX Aroa Biosurgery
3.1x15.65%US$147.41m
IMC Immuron
2.4xn/aUS$11.51m
BNO Bionomics
2.4x-5.32%US$9.52m
IMU 20.5xIndustry Avg. 15.2xNo. of Companies8PS01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IMU is expensive based on its Price-To-Sales Ratio (20.5x) compared to the Australian Biotechs industry average (15.2x).

Price to Sales Ratio vs Fair Ratio

What is IMU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.5x
Fair PS Ratio45.4x

Price-To-Sales vs Fair Ratio: IMU is good value based on its Price-To-Sales Ratio (20.5x) compared to the estimated Fair Price-To-Sales Ratio (45.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.30
AU$7.21
+2,263.93%
88.63%AU$13.60AU$0.82n/a2
Nov ’26AU$0.36
AU$7.21
+1,875.34%
88.63%AU$13.60AU$0.82n/a2
Apr ’26AU$1.05
AU$8.16
+674.19%
63.01%AU$15.30AU$3.40n/a3
Mar ’26AU$1.26
AU$8.16
+548.65%
63.01%AU$15.30AU$3.40n/a3
Feb ’26AU$1.22
AU$8.61
+603.70%
67.01%AU$16.66AU$3.40n/a3
Jan ’26AU$1.26
AU$8.61
+584.68%
67.01%AU$16.66AU$3.40n/a3
Dec ’25AU$1.29
AU$10.03
+676.32%
55.52%AU$16.66AU$3.40n/a4
Nov ’25AU$1.53
AU$10.03
+555.56%
55.52%AU$16.66AU$3.40AU$0.364
Oct ’25AU$1.70
AU$10.03
+490.00%
55.52%AU$16.66AU$3.40AU$0.304
Sep ’25AU$2.11
AU$12.01
+469.89%
41.49%AU$16.66AU$5.10AU$0.283
Aug ’25AU$1.80
AU$12.01
+566.67%
41.49%AU$16.66AU$5.10AU$0.253
Jul ’25AU$1.87
AU$12.01
+542.42%
41.49%AU$16.66AU$5.10AU$0.483
Jun ’25AU$2.28
AU$12.01
+427.36%
41.49%AU$16.66AU$5.10AU$0.513
May ’25AU$2.86
AU$12.01
+320.63%
41.49%AU$16.66AU$5.10AU$0.823
Apr ’25AU$3.57
AU$11.45
+220.64%
50.43%AU$16.66AU$3.40AU$1.053
Mar ’25AU$4.08
AU$11.90
+191.67%
50.63%AU$16.66AU$3.40AU$1.263
Feb ’25AU$3.40
AU$11.90
+250.00%
50.63%AU$16.66AU$3.40AU$1.223
Jan ’25AU$3.74
AU$11.90
+218.18%
50.63%AU$16.66AU$3.40AU$1.263
Dec ’24AU$3.40
AU$11.90
+250.00%
50.63%AU$16.66AU$3.40AU$1.293
Nov ’24AU$1.43
AU$12.47
+773.02%
52.19%AU$18.36AU$3.40AU$1.533
AU$7.21
Fair Value
95.8% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/20 00:49
End of Day Share Price 2025/11/20 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imugene Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Hunter DiamondDiamond Equity Research LLC
Dennis HulmeEdison Investment Research